On May 8, 2008, Shapiro, Gideon; Moncuso, John; Pierre, Tessier; Leit, Silvana; Deziel, Robert; David, Smil; Richard, Chesworth; Chantigny, Yves Andre; Patrick, Beaulieu published a patent.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate The title of the patent was Preparation of tricyclic hydroxamic acids as inhibitors of histone deacetylase. And the patent contained the following:
The title compounds I [Z = N(R1)OR2, H; L = a bond, N(OR2); when L = N(OR2), Z = H; when Z = H, L = N(OR2); R1, R2 = H, alkyl, aryl, etc.; J = a bond, :CH-, alkyl, alkyl(heteroalkyl)alkyl, etc.; Q = diazepine, pyrrolidine, diazabicyclo[3.3.1]nonane, etc.; B = dibenzo[b,f][1,4]oxazepine, benzo[b]pyrido[2,3-e][1,4]diazepine, benzo[f]thieno[2,3-b][1,4]oxazepine, etc.;], useful for the inhibition of histone deacetylase, were prepared E.g., a 3-step synthesis of II, starting from 10,11-dihydrodibenz[b,f][1,4]oxazepin-11-one, was given. All exemplified compounds I have an IC50 of ≤ 10 μM against one of more of HDAC-1 through HDAC-11 (data for representative compounds I were given). Pharmaceutical composition comprising the compound I and methods of treating polyglutamine (polyQ) expansion diseases such as Huntington’s disease, are disclosed. The experimental process involved the reaction of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(cas: 227940-70-7).Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
The Article related to tricyclic hydroxamic acid preparation histone deacetylase hdac inhibitor, huntington’s disease treatment tricyclic hydroxamic acid preparation hdac inhibitor, dibenzoxazepine preparation histone deacetylase hdac inhibitor dentatorubralpallidoluysian atrophy treatment and other aspects.Safety of tert-Butyl 7-benzyl-9-oxo-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics